0102030405
Lenvatinib CAS No. 417716-92-8 Antineoplastic Pharmaceutical Raw Material
02
introduce
introduce
Lenvatinib is a potent, oral multi-targeted tyrosine kinase inhibitor and core antineoplastic API. It selectively inhibits VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT kinases, blocking tumor angiogenesis and proliferation. Approved for treating advanced thyroid cancer, hepatocellular carcinoma (HCC), and renal cell carcinoma (RCC).
Our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply for clinical use and biomedical research.
02
Physical and chemical properties
Lenvatinib exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Melting Point: >216°C
- Boiling Point: 627.2±55.0 °C at 760 mmHg
- Density: 1.5±0.1 g/cm³
- Solubility: Soluble in DMSO (≥50 mg/mL)
- Melting Point: >216°C
- Boiling Point: 627.2±55.0 °C at 760 mmHg
- Density: 1.5±0.1 g/cm³
- Solubility: Soluble in DMSO (≥50 mg/mL)
1. Broad and Targeted Multi-Target Coverage
As an oral multi-target tyrosine kinase inhibitor, it can simultaneously inhibit multiple targets related to tumor angiogenesis and proliferation, including VEGFR1-3, FGFR1-4, PDGFRα, KIT and RET. Among them, it has the strongest inhibitory activity against VEGFR2/3. Compared with single-target inhibitors, it can block tumor growth pathways more comprehensively.
As an oral multi-target tyrosine kinase inhibitor, it can simultaneously inhibit multiple targets related to tumor angiogenesis and proliferation, including VEGFR1-3, FGFR1-4, PDGFRα, KIT and RET. Among them, it has the strongest inhibitory activity against VEGFR2/3. Compared with single-target inhibitors, it can block tumor growth pathways more comprehensively.
2. Filling the Gap in Refractory Cancer Treatment
In the treatment of radioactive iodine-refractory differentiated thyroid cancer, the median survival time of patients treated with lenvatinib can reach 18 months, while that of the placebo group is only 3 months, with a significant improvement in efficacy. Compared with sorafenib, a similar targeted drug (the first targeted drug approved for the treatment of this type of thyroid cancer), it provides a better treatment option for patients with such refractory cancers.
In the treatment of radioactive iodine-refractory differentiated thyroid cancer, the median survival time of patients treated with lenvatinib can reach 18 months, while that of the placebo group is only 3 months, with a significant improvement in efficacy. Compared with sorafenib, a similar targeted drug (the first targeted drug approved for the treatment of this type of thyroid cancer), it provides a better treatment option for patients with such refractory cancers.
3. Dual Mechanism of Action for More Comprehensive Anti-Tumor Effect
It not only blocks tumor angiogenesis by inhibiting the VEGFR family, but also directly inhibits tumor cell proliferation by inhibiting targets such as FGFR and PDGFRα. Compared with drugs that only act on a single pathway of angiogenesis or cell proliferation, it can suppress tumor development from two core links.
Its core application is targeted therapy for malignant tumors, suitable for a variety of refractory or advanced cancers. The specific scenarios include:
1. Core Indication:
Treating locally recurrent or metastatic, radioactive iodine-refractory differentiated thyroid cancer (DTC), which is its primary approved treatment scenario.
2. Treatment of Other Solid Tumors: Used for the treatment of advanced or metastatic renal cell carcinoma; it can also be used for the treatment of hepatocellular carcinoma, and related preparations have been applied in clinical practice.
3. Potential Application Value: In animal experiments, it has a tumor growth inhibitory effect on small cell lung cancer xenograft models, with the potential to be expanded for the treatment of other solid tumors.
2. Treatment of Other Solid Tumors: Used for the treatment of advanced or metastatic renal cell carcinoma; it can also be used for the treatment of hepatocellular carcinoma, and related preparations have been applied in clinical practice.
3. Potential Application Value: In animal experiments, it has a tumor growth inhibitory effect on small cell lung cancer xenograft models, with the potential to be expanded for the treatment of other solid tumors.
We implement strict full-process quality control, with each batch of Lenvatinib undergoing rigorous testing of key indicators including purity, solubility, stability, enantiomeric excess, and biological activity to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and research needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and research needs.
As a leading multi-targeted tyrosine kinase inhibitor, Lenvatinib has become a cornerstone in treating multiple solid tumors, revolutionizing anti-angiogenic cancer therapy. With its broad efficacy, convenient administration, exceptional quality, and reliable supply capacity, we are committed to providing high-quality Lenvatinib API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Lenvatinib to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Lenvatinib to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.